Wegovy®

Your safety is our first priority. Learn more about key medication details, side effects, and other important info about your treatment below.

Common Side effects

  • Nausea
  • Diarrhea
  • Vomiting

Prescribing information

WEGOVY® (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity:

  • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.
  • to reduce excess body weight and maintain weight reduction long term in:
    • Adults and pediatric patients aged 12 years and older with obesity
    • Adults with overweight in the presence of at least one weight-related comorbid condition.

Limitations of Use:

  • Co-administration with other semaglutide-containing products or any GLP-1 receptor agonist is not recommended.
  • The safety and efficacy of coadministration with other products for weight management have not been established.
  • There is limited experience from clinical trials with WEGOVY® in patients with a history of pancreatitis. It is unknown if patients with a history of pancreatitis are at a higher risk for development of pancreatitis on WEGOVY®.

Important safety information

WARNING: RISK OF THYROID C-CELL TUMORS

See full prescribing information for complete boxed warning.

  • In rodents, semaglutide causes thyroid C-cell tumors in clinically relevant exposures. It is unknown whether WEGOVY® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
  • WEGOVY® is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.

Do not take WEGOVY® if you:

  • Have a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
  • Have been diagnosed with Diabetes (Type 1)
  • Have been diagnosed with pancreatitis or history of pancreatitis
  • Have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food
  • Have a known allergy to semaglutide/any other GLP-1 drug or any of the inactive ingredients in WEGOVY®.
  • Injectable WEGOVY® inactive ingredients include: di-sodium phosphate dihydrate, sodium chloride, water for injection, and hydrochloric acid or sodium hydroxide may be added to adjust pH.
  • Oral WEGOVY® inactive ingredients include: magnesium stearate and Salcaprozate sodium.
  • Have a history of suicidal attempts or active suicidal ideation

WARNINGS AND PRECAUTIONS

  • Acute Pancreatitis: Has occurred in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
  • Acute Gallbladder Disease: Has occurred in clinical trials. If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated.
  • Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of insulin secretagogue or insulin may be necessary. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
  • Acute Kidney Injury: Has occurred. Monitor renal function when initiating or escalating doses of WEGOVY® in patients reporting severe adverse gastrointestinal reactions or in those with renal impairment reporting severe adverse gastrointestinal reactions.
  • Hypersensitivity Reactions: Anaphylactic reactions and angioedema have been reported postmarketing. Discontinue WEGOVY® if suspected and promptly seek medical advice.
  • Females and males of reproductive potential: Discontinue WEGOVY® at least 2 months before a planned pregnancy because of the long half-life of semaglutide.
  • Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue WEGOVY® immediately.
  • Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: Has been reported in trials with WEGOVY®. Patients with a history of diabetic retinopathy should be monitored.
  • Heart Rate Increase: Monitor heart rate at regular intervals.
  • Suicidal Behavior and Ideation: Monitor for depression or suicidal thoughts. Discontinue WEGOVY® if symptoms develop.

Side Effects Most common side effects (incidence ≥ 5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

DRUG INTERACTIONS WEGOVY® delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue WEGOVY®.
  • Females and Males of Reproductive Potential: Discontinue WEGOVY® at least 2 months before a planned pregnancy because of the long half-life of semaglutide.
The health assessment available on this website does not create a provider-patient relationship between the individual completing the assessment and RX Optimal. Medical services, including clinical assessment and prescribing, are provided by its affiliated professional medical practices. Licensed providers apply clinical protocols and exclusionary criteria to determine whether an individual qualifies for treatment. A provider will conduct a telehealth consultation to evaluate medical appropriateness before any prescription is issued. Providers retain sole discretion over all prescribing decisions. A prescription is never guaranteed.

All claims and results referenced on this website reflect self-reported data from members enrolled in the RX Optimal healthcare membership program, which includes telehealth consultations with licensed providers and, where clinically appropriate, compounded GLP-1 medications. Members reported their weight at initial intake and at regular intervals thereafter. Individual results vary and depend on factors including starting weight, program adherence, diet, exercise, and the clinical recommendations of the treating provider. Compounded medications are prepared by state-licensed 503A compounding pharmacies. These medications are not FDA approved and have not been evaluated by the FDA for safety, efficacy, or quality. The decision to prescribe compounded medications is an individualized clinical determination made by the treating provider based on the patient's medical history, current health status, and telehealth assessment. RX Optimal does not manufacture or compound medications. Actual medication appearance may differ from website imagery.

Pharmacy Partners: Prescriptions are filled by independently owned and operated state-licensed 503A compounding pharmacies within the RX Optimal pharmacy network. Each pharmacy maintains its own state board of pharmacy licenses and operates under applicable federal and state compounding regulations.

Individual results vary based on starting weight, medical history, program adherence, diet, and exercise. The weight loss figures referenced on this website are based on self-reported data from RX Optimal members and are not derived from clinical trials or peer-reviewed studies. Not all members experience the same results. A prescription is never guaranteed and is at the sole discretion of the treating provider. Consult your healthcare provider before beginning any weight management program.

The RX Optimal healthcare membership includes access to telehealth consultations with licensed providers and, where clinically appropriate, prescription fulfillment through the RX Optimal pharmacy network. Medical services are provided by affiliated professional medical practices, independently owned and operated. RX Optimal provides the technology platform and administrative services and does not provide medical services or make prescribing decisions. No data, photographs, claims, or other information presented on this website are derived from clinical trials or published peer-reviewed studies. All results and testimonials are representative of individual RX Optimal member experiences only.

For support: help@rxoptimal.com

Footer Background
Brand LogoVerify Approval for www.altrx.comMade in USA

We maintain administrative, technical, and physical safeguards designed to protect your health information.

HomeContact UsBlogsAbout UsTerms of Service
Privacy PracticesTelehealth ConsentBill of RightsFor California ResidentsRefund & Cancellation PolicyConsumer Health Data Privacy PolicyPrivacy PolicyDo Not Sell
All medical services, including clinical assessments, treatment planning, and prescribing decisions are provided by affiliated professional medical practices, which are independently owned and operated. RX Optimal provides the technology platform and administrative coordination services that connect you with your healthcare provider. RX Optimal does not provide medical services, does not employ healthcare providers, does not participate in clinical decisions, and does not practice medicine.